These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28853141)

  • 61. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].
    Schmidt T; Sisic L; Sterzing F; Haag GM; Kunzmann R; Grenacher L; Weichert W; Jäger D; Büchler MW; Ott K
    Chirurg; 2015 Oct; 86(10):955-62. PubMed ID: 25715974
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
    Mariette C; Dahan L; Mornex F; Maillard E; Thomas PA; Meunier B; Boige V; Pezet D; Robb WB; Le Brun-Ly V; Bosset JF; Mabrut JY; Triboulet JP; Bedenne L; Seitz JF
    J Clin Oncol; 2014 Aug; 32(23):2416-22. PubMed ID: 24982463
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
    Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
    Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma.
    Blom RL; Sosef MN; Nap M; Lammering G; van den Berkmortel F; Hulshof MC; Meijer SL; Wilmink HW; van Berge Henegouwen MI
    Dis Esophagus; 2014; 27(4):380-7. PubMed ID: 24006852
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
    Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
    Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
    Kelsey CR; Chino JP; Willett CG; Clough RW; Hurwitz HI; Morse MA; Bendell JC; D'Amico TA; Czito BG
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):770-6. PubMed ID: 17889266
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.
    Horgan AM; Darling G; Wong R; Guindi M; Liu G; Jonker DJ; Lister J; Xu W; MacKay HM; Dinniwell R; Kim J; Pierre A; Shargall Y; Asmis TR; Agboola O; Seely AJ; Ringash J; Wells J; Marginean EC; Haider M; Knox JJ
    Dis Esophagus; 2016 Nov; 29(8):1152-1158. PubMed ID: 26663741
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with computed tomography in esophageal cancer patients.
    Hulshoff JB; Smit JK; van der Jagt EJ; Plukker JT
    Am J Surg; 2014 Jul; 208(1):73-9. PubMed ID: 24476969
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?
    Meguid RA; Hooker CM; Taylor JT; Kleinberg LR; Cattaneo SM; Sussman MS; Yang SC; Heitmiller RF; Forastiere AA; Brock MV
    J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1309-17. PubMed ID: 19931663
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis.
    Wang HH; de Heer EC; Hulshoff JB; Kats-Ugurlu G; Burgerhof JGM; van Etten B; Plukker JTM; Hospers GAP;
    Ann Surg Oncol; 2021 Jul; 28(7):3951-3960. PubMed ID: 33249520
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.
    Toxopeus EL; Nieboer D; Shapiro J; Biermann K; van der Gaast A; van Rij CM; Steyerberg EW; van Lanschot JJ; Wijnhoven BP
    Radiother Oncol; 2015 Jun; 115(3):392-8. PubMed ID: 26116340
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Organ-sparing treatment in oesophagus cancer: feasible and safe?].
    Noordman BJ; Wijnhoven BPL; Lagarde SM; Spaander MCW; Valkema R; van Lanschot JJB
    Ned Tijdschr Geneeskd; 2017; 161():D1818. PubMed ID: 29125080
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction.
    DeCesaris CM; Berger M; Choi JI; Carr SR; Burrows WM; Regine WF; Simone CB; Molitoris JK
    J Gastrointest Oncol; 2020 Aug; 11(4):663-673. PubMed ID: 32953150
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Locoregional Residual Esophageal Cancer after Neo-adjuvant Chemoradiotherapy and Surgery Regarding Anatomic Site and Radiation Target Fields: A Histopathologic Evaluation Study.
    Faiz Z; Kats-Ugurlu G; Mui VEM; Karrenbeld A; Burgerhof HGM; Plukker JTM; Muijs CT
    Ann Surg; 2022 Jun; 275(6):e759-e765. PubMed ID: 32740246
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
    Li Q; Liu T; Ding Z
    Front Immunol; 2022; 13():1051841. PubMed ID: 36569908
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Imaging and scopes? It's bloody time for another branch in the decision tree.
    Litle VR
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2243-2244. PubMed ID: 29482847
    [No Abstract]   [Full Text] [Related]  

  • 80. Effects of Neoadjuvant 5-Fluorouracil and Cisplatin Therapy in Patients with Clinical Stage II/III Esophageal Squamous Cell Carcinoma.
    Konishi H; Fujiwara H; Shiozaki A; Shoda K; Kosuga T; Kubota T; Okamoto K; Otsuji E
    Anticancer Res; 2018 Feb; 38(2):1017-1023. PubMed ID: 29374735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.